渴络欣联合依那普利治疗糖尿病肾病的临床研究

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (2): 211-214.

渴络欣联合依那普利治疗糖尿病肾病的临床研究

刘雷, 李良志, 何先红, 汤跃武, 史继红, 刘春秋, 吴泽成, 王军

重庆市三峡中心医院肾内科,重庆 404100

收稿日期:2011-11-14 修回日期:2011-12-12 出版日期:2012-02-26 发布日期:2012-03-12
通讯作者: 何先红,男,副主任医师,研究方向:慢性肾脏病的防治。Tel: 023-58103300 E-mail: hxh243@126.com
作者简介:刘雷,男,硕士,主治医师,研究方向:糖尿病肾病的发病机制及防治。Tel: 023-58103563 E-mail: liulei82222@163.com

Cinical study of Keluoxin combined with enalapril in treatment of diabetic nephropathy

LIU Lei, LI Liang-Zhi, HE Xian-Hong, TANG Yue-wu, SHI Ji-hong, LIU Chun-qiu, WU Ze-cheng, WANG Jun

Department of Nephrology,Sanxia Central Hospital, Chongqing 404100, China

Received:2011-11-14 Revised:2011-12-12 Online:2012-02-26 Published:2012-03-12

摘要/Abstract

摘要： 目的: 观察渴络欣联合依那普利治疗糖尿病肾病(DN)的临床疗效。方法: 早期糖尿病肾病(DN Ⅲ期)患者43例和临床糖尿病肾病(DN Ⅳ期)37例分别随机分为依那普利对照组和渴络欣联合依那普利治疗组,疗程均为2个月。结果: 与治疗前比较,治疗组治疗后血清总胆固醇(TC)、血清甘油三酯(TG)、血清低密度脂蛋白胆固醇(LDL-C)明显下降(P<0.05,P<0.01),血清高密度脂蛋白胆固醇(HDL-C)明显上升(P<0.05),对照组上述指标变化无统计学意义(P>0.05)。治疗后治疗组和对照组早期DN患者尿白蛋白排泄率(UAER)、尿α₁微球蛋白(α₁-MG)、尿β₂微球蛋白(β₂-MG)均明显减少(P<0.05,P<0.01),而治疗组较对照组疗效更为显著(P<0.05)。对临床DN患者的尿蛋白定量、尿α₁-MG、尿β₂-MG、血白蛋白(ALB),治疗组和对照组均改善显著(P<0.05,P<0.01),但治疗组优于对照组(P<0.05);对临床DN患者的血肌酐(Cr),对照组无明显改善(P>0.05),但治疗组却改善显著(P<0.05)。结论: 渴络欣联合依那普利治疗DN疗效肯定,在减少尿蛋白、改善肾功能方面明显优干单用依那普利,提示两药合用在延缓DN进展方面能够发挥各自的优势,起到协同作用。

关键词: 糖尿病肾病, 渴络欣, 依那普利

Abstract: AIM: To study the clinical curative effect of keluoxin collocystis combined with enalapril in treatment of diabetic nephropathy.METHODS: Forty three patients with early diabetic nephropathy and 37 patients with clinical diabetic nephropathy were randomly divided into enalapril control group and keluoxin combined with enalapril treated group,the tota1 course of treatment was 2 months.RESULTS: After 2 months of treatment,the levels of TC,TG and LDL-C in treated group were decreased obviously (P<0.05,P<0.01),the level of HDL-C was elevated obviously (P<0.05)in treated group,while there were no significant difference of TG, TC, LDL-C and HDL-C in control group.The UAER, α₁-MG、β₂-MG were decreased significantly in both groups in early diabetic nephropathy(P<0.05,P<0.01),but more significant in treated group than that in control group (P<0.05).The urine protein quantitative, urinaryα₁-MG, urinaryβ₂-MG and blood albumin were improved significantly in both groups in clinical diabetic nephropathy(P<0.05,P<0.01),but more significant in treated group than that in control group (P<0.05);the serum creatinine (Scr) in the clinical DN patients of control group was no obvious improvement (P>0.05),but the Scr in treatment group was improved significantly (P<0.05).CONCLUSION: Keluoxin combined with enalapril in treatment of DN patients has better effectiveness in reducing albuminuria and in improving renal function than enalapril alone.The data indicates that the combination of the two drugs can help each other against DN development. Keluoxin combined with enalapril are effective in treatment of diabetic nephropathy.

Key words: Diabetic nephropathy, Keluoxin, Enalapril

中图分类号:

R587.2

刘雷, 李良志, 何先红, 汤跃武, 史继红, 刘春秋, 吴泽成, 王军. 渴络欣联合依那普利治疗糖尿病肾病的临床研究[J]. 中国临床药理学与治疗学, 2012, 17(2): 211-214.

LIU Lei, LI Liang-Zhi, HE Xian-Hong, TANG Yue-wu, SHI Ji-hong, LIU Chun-qiu, WU Ze-cheng, WANG Jun. Cinical study of Keluoxin combined with enalapril in treatment of diabetic nephropathy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 211-214.

[1]	金依依, 周科挺, 杨成成, 徐萍, 朱素燕. 蛇床子素抑制NF-κB和p38/MAPK改善糖尿病诱导的肾脏损伤[J]. 中国临床药理学与治疗学, 2022, 27(6): 622-631.
[2]	刘鹏, 赵海玲, 申正日, 王晨, 王昀, 邱新萍, 李平. 糖肾方抑制TGF-β1/Smad3通路促进小鼠肾小管上皮细胞胆固醇流出[J]. 中国临床药理学与治疗学, 2021, 26(1): 1-9.
[3]	赵韶静，曾艳，李正东，张华. 左卡尼汀对大鼠糖尿病肾病的保护作用分析[J]. 中国临床药理学与治疗学, 2019, 24(3): 278-282.
[4]	姚佳，乔迪，郭鑫，崔昌萌. 桑叶中1-脱氧野尻霉素对糖尿病肾病大鼠的治疗作用[J]. 中国临床药理学与治疗学, 2018, 23(5): 517-523.
[5]	姜莉莉，毛利民，胡思佳，彭应枝. 肾衰宁颗粒对糖尿病肾病大鼠肾组织NF-kB及PPAR-gamma表达的影响[J]. 中国临床药理学与治疗学, 2018, 23(2): 132-137.
[6]	傅永锦，夏雪怡，张小牧，刘艳波，潘竞锵，吕俊华. 川芎嗪对糖尿病肾病大鼠下调HMGB1表达及降低RAGEs作用[J]. 中国临床药理学与治疗学, 2017, 22(8): 846-851.
[7]	俞晓忆，周芷若，谢媛，孙润彬，费菲，高浩雪，黄京秋，阿基业，王广基. 糖尿病肾病细胞模型三羧酸循环代谢异常和机制初探[J]. 中国临床药理学与治疗学, 2017, 22(5): 481-489.
[8]	贾会玉, 李中南, 陈光亮. 转化生长因子-β₁介导的Smads和MAPKs信号通路在糖尿病肾病中的作用及其抑制剂研究进展[J]. 中国临床药理学与治疗学, 2015, 20(10): 1171-1176.
[9]	朱泓霞, 王雪锋, 徐倩. 硝苯地平缓释片分别联用马来酸依那普利片与酒石酸美托洛尔片治疗高危高血压的临床疗效观察[J]. 中国临床药理学与治疗学, 2014, 19(10): 1167-1170.
[10]	范秋灵, 肇晓明, 蒲实, 李卅立, 杨刚, 姜奕, 王力宁. 坎地沙坦不同治疗时机对2型糖尿病KK/Ta小鼠肾脏血管紧张素1型和2型受体表达的影响[J]. 中国临床药理学与治疗学, 2012, 17(6): 627-633.
[11]	韩素芳. 血管紧张素转换酶抑制剂联合血管紧张素II受体拮抗剂对糖尿病肾病肾功能临床疗效的Meta分析[J]. 中国临床药理学与治疗学, 2012, 17(11): 1257-1262.
[12]	费美姣. 厄贝沙坦联合古拉定对糖尿病肾病的保护作用研究[J]. 中国临床药理学与治疗学, 2012, 17(11): 1272-1275.
[13]	任传永, 徐亮. 前列地尔治疗糖尿病肾病的时相性观察[J]. 中国临床药理学与治疗学, 2011, 16(7): 812-814.
[14]	倪连松, 金洁娜, 郑景晨, 沈飞霞. 阻断p38丝裂原活化蛋白激酶信号通路对高糖培养肾小球系膜NF-κB信号通路调控影响[J]. 中国临床药理学与治疗学, 2011, 16(1): 13-17.
[15]	沈水娟, 胡作祥, 王时敏, 李青华. 黄葵胶囊联合雷公藤多苷片治疗Ⅳ期糖尿病肾病的疗效观察[J]. 中国临床药理学与治疗学, 2011, 16(1): 85-88.